ArticleInfectious disease reports2022
Evaluating the Use of Dalbavancin for Off-Label Indications.
Article in Infectious disease reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Operationalizing Single-Dose Long-Acting Lipoglycopeptides for Treatment of ABSSSI in a U.S. Community Hospital Emergency Department.Clinical drug investigation · 2026Article
- Practical vs Recent Clinical Trial Use Of Dalbavancin.JAMA network open · 2026Article
- Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children.BMC research notes · 2026Article
- Delivery of Outpatient Parenteral Antimicrobial Therapy (OPAT) in an Ever-Changing National Health Service (UK): Benefits, Barriers, and Opportunities.Antibiotics (Basel, Switzerland) · 2025Review
- Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials.The Journal of antimicrobial chemotherapy · 2025Article
- Article
- Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.Antibiotics (Basel, Switzerland) · 2025Review
- In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.Infection · 2024Article
- Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.JAC-antimicrobial resistance · 2024Article
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.Journal of clinical medicine · 2023Review
- A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.Antibiotics (Basel, Switzerland) · 2023Review
- Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic approved for skin and soft-tissue infections. Post-marketing experience suggests dalbavancin is being used for off-label indications that normally require long-term intravenous (IV) antibiotics; however, data assessing this off-label usage are limited. The purpose of this study was to evaluate the real-world efficacy, safety, and financial impact of off-label dalbavancin use. (2) Methods: This is a retrospective, observational study conducted within a 4-hospital health system. Adult patients who received dalbavancin from January 2018 to January 2021 for an off-label indication were included. The primary outcome was clinical success at 90 days. Secondary outcomes included safety (nephrotoxicity and hepatotoxicity). A pharmacoeconomic analysis was performed by comparing the cost of dalbavancin to the anticipated cost of patient stay if standard IV therapy was given. (3) Results: Forty-eight patients met study criteria. Indications included osteomyelitis (54%), endocarditis (23%), bacteremia (15%), and prosthetic joint infection (8%). The predominant organism was
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.